Evommune, Inc. (EVMN)
NYSE:EVMN
Want to see EVMN full AI Analyst Report?
EVMN Stock Chart & Stats
$27.45
--
Market closed
$27.45
--
Day’s Range― - ―
52-Week Range$13.89 - $33.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)935.27K
Market Cap
$851.11M
Enterprise Value$268.97M
Total Cash (Recent Filing)$149.20M
Total Debt (Recent Filing)$2.06M
Price to Earnings (P/E)―
Beta0.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,018,370
10 Day Avg. Volume412,591
30 Day Avg. Volume935,274
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.63
Price to Sales (P/S)41.51
P/FCF Ratio-7.04
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue20.69
Enterprise Value/Gross Profit23.16
Enterprise Value/Ebitda-3.90
Forecast
1Y Price Target
$52.00Price Target Upside89.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet RecapitalizationA dramatic reduction in debt and a swing to positive equity materially lowers financial leverage and bankruptcy risk. This strengthens the company’s ability to fund clinical development through near-term milestones, improves counterparty confidence, and increases strategic optionality for partnerships or M&A.
Sustained Revenue GrowthThree-year revenue growth demonstrates growing commercial or collaboration receipts, indicating product/partner traction and a rising top line base. If sustained, this revenue scale helps absorb fixed R&D/G&A costs, improves gross margin leverage potential, and reduces reliance on dilutive financings.
Clinical POC + Material FinancingPhase 2a proof-of-concept for EVO301 validates the IL-18 approach, lowering technical risk for that program, while the $125M financing materially extends runway. Together they reduce near-term execution risk, support planned Phase 2b/expansion, and improve prospects for partnering or commercialization.
Bears Say
Worsening Cash BurnDeepening negative operating and free cash flow over multiple years is a structural concern: it necessitates repeated external funding unless revenues scale or costs are cut. Persistent burn constrains strategic flexibility, pressures liquidity planning, and raises dilution risk for shareholders over time.
Large, Persistent Net LossesMulti-year, sizable net losses show the cost base outpacing revenue scale, reflecting heavy R&D and G&A that are not yet offset by product revenues. Until clinical programs convert to commercial sales or high-margin partnerships, profitability remains distant and financial sustainability depends on successful de‑risking.
Reliance On Continued FinancingAlthough recapitalized, management must sustain discipline and secure further resources if trials progress or timelines slip. The business remains financing-dependent; future capital raises could be dilutive and are contingent on trial outcomes and market appetite, posing execution and governance risks.
Evommune, Inc. News
EVMN FAQ
What was Evommune, Inc.’s price range in the past 12 months?
Evommune, Inc. lowest stock price was $13.88 and its highest was $33.20 in the past 12 months.
What is Evommune, Inc.’s market cap?
Evommune, Inc.’s market cap is $851.11M.
When is Evommune, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Evommune, Inc.’s earnings last quarter?
Currently, no data Available
Is Evommune, Inc. overvalued?
According to Wall Street analysts Evommune, Inc.’s price is currently Undervalued.
Does Evommune, Inc. pay dividends?
Evommune, Inc. does not currently pay dividends.
What is Evommune, Inc.’s EPS estimate?
Evommune, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evommune, Inc. have?
Evommune, Inc. has 36,018,370 shares outstanding.
What happened to Evommune, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evommune, Inc.?
Currently, no hedge funds are holding shares in EVMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evommune, Inc. Stock Smart Score
Company Description
Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
EVMN Stock 12 Month Forecast
Average Price Target
$52.00
▲(89.44% Upside)
Ownership Overview
52.56% Insiders
10.70% Mutual Funds
0.69% Other Institutional Investors
33.42% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---